AGLE-325

**AGLE-325** is a preclinical enzyme-based therapeutic candidate developed by Aeglea BioTherapeutics for the treatment of **cystinuria**, a rare metabolic disorder characterized by excessive cystine excretion in urine leading to recurrent kidney stones and potential renal damage. It is engineered to enzymatically degrade **cystine**, an amino acid, thereby reducing urinary cystine levels to prevent stone formation and mitigate disease progression. The program leverages advanced protein engineering to optimize enzyme activity, stability, and pharmacokinetics, with preclinical studies focused on safety, efficacy, and IND-enabling activities.[1][3][4][7]